Pharmaceutical and healthcare information provider IMS Health, US, has announced the expansion of IMS Oncology Analyzer to additional cities in China. The market measurement tool enables IMS's pharmaceutical clients to assess treatments and guide commercial decisions in the country's fast-growing, more than $1.5 billion oncology market.
IMS Oncology Analyzer now covers twelve Tier 1 and Tier 2 cities in China, providing the clinically comprehensive view of cancer care from first diagnosis. Delivering commercial and clinical insight into oncology product uptake and treatment patterns, IMS Oncology Analyzer claims to be the only anonymised patient-level information resource in China that captures all cancer treatment modalities across all tumor types.
By the end of 2011, China is expected to become the world's third-largest pharmaceutical market, growing more than 20 percent annually. Oncology, the largest therapeutic area globally, is among the top five therapy classes in China, where compound annual growth has exceeded 25 percent over the past five years.
IMS Oncology Analyzer is an evidence-based, quantitative market research tool to measure life cycle management strategies, product performance plans, new indication opportunities and many other relevant commercial planning activities. In addition to China, the offering is available in the UK, France, Italy, Spain, Germany, Turkey, the Netherlands, Japan, Korea and Taiwan.
Search for more oncology related information
Get customisable STM news alerts in your Mobile. Visit http://www.scopeknowledge.com/scoope.jar via your mobile browser to download the SCOOPE application
